Premium
Early Experience with the Use of Celecoxib in a Child and Adolescent Population
Author(s) -
Lie Henry KH,
Turner Sean C
Publication year - 2002
Publication title -
journal of pharmacy practice and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.222
H-Index - 22
eISSN - 2055-2335
pISSN - 1445-937X
DOI - 10.1002/jppr200232127
Subject(s) - medicine , celecoxib , adverse effect , demographics , population , pediatrics , demography , environmental health , sociology
Objective: To describe the use of celecoxib, a new selective cyclo‐oxygenase 2 (COX‐2) inhibitor, in a child and adolescent population. Method: A twelve‐month retrospective analysis of the use of celecoxib within a major paediatric teaching hospital was undertaken. Data collected for each patient included patient demographics, indication for use, length of treatment, dose administered and reported adverse effects. Results: Twelve patients received celecoxib over a 12‐month period. These patients can be divided into subgroups, including those with existing haematological disorders e.g. von Willebrand's disease with co‐existing morbidities of joint swelling and pain, and those patients who had previously reported adverse events to non‐selective non‐steroidal anti‐inflammatory drugs. Doses used in six children aged 12 years of age or less ranged from 2.4 to 6.3 mg/kg/day. The remaining patients were adolescents and were prescribed adult doses. In all patients celecoxib was well tolerated. Conclusion: Celecoxib appears to have a role in child and adolescent therapy. However, this role is not well established and it is essential that large, well‐designed studies to determine the dose, safety, efficacy and place of celecoxib in the treatment of children and adolescents be undertaken.